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Background: Clinical dextrans, such as Dextran 40 and Dextran 70, are associated with anaphylactoid reactions caused by
dextran-reactive immunoglobulin G antibodies. When infused immediately before clinical dextrans, dextran 1 signifi-
cantly reduces the incidence of severe anaphylactoid reactions. The objective of the study was to describe the frequency
and characteristics of reports submitted to the United States Food and Drug Administration (FDA) for anaphylaxis or
anaphylactoid events after clinical dextran administration.
Methods: We searched the FDA’s Adverse Event Reporting System for reports associated with a clinical dextran and
describing anaphylaxis/anaphylactoid reactions. Our case definition for a probable anaphylaxis/anaphylactoid event
required signs or symptoms from at least two body systems, with at least one sign or symptom being hypotension,
vasodilation, or respiratory difficulty, and onset within 60 minutes. Other reports were considered possible cases if the
reporter specifically described the reaction as anaphylaxis or an anaphylactoid reaction. Premier RxMarket Advisor
provided estimates of total US hospitalizations with clinical dextran or dextran 1 administration from 2000 to 2004,
based on discharge billing data from a sample of US hospitals. The IMS National Sales Perspective provided estimates of
total doses of dextrans sold in the United States from 1999 to 2004, based on volumes of dextrans sold in a sample of
retail and nonretail outlets.
Results: The FDA received 366 clinical dextran adverse event reports from 1969 to 2004, of which 90 (24.6%) were
anaphylaxis/anaphylactoid events. The ratio of hospitalizations where clinical dextran was administered to hospitaliza-
tions where dextran 1 was administered was 28.4:1. The expected ratio would be 1:1 if all clinical dextran patients had
received dextran 1 pretreatment. The ratio of clinical dextran doses sold to dextran 1 doses sold in the United States was
38.6:1.
Conclusions: A high proportion of adverse event reports for clinical dextrans described anaphylaxis or anaphylactoid
reactions. Hospital discharge and product sales data suggest that dextran 1 has not been used consistently before clinical
dextran administration in recent years. To reduce the risk of anaphylactoid reactions, physicians should consider routine
administration of dextran 1 before the infusion of a clinical dextran. (J Vasc Surg 2006;43:1004-9.)Dextrans were first introduced into clinical practice as
colloid plasma volume expanders in 1947.1 Today, Dextran
40, 70, and 75, collectively known as clinical dextrans, are
also widely used for postoperative thromboembolic pro-
phylaxis. As described in this issue’s editorial on dextrans by
Dr Ljungstrom, clinical dextrans are commonly used in
both vascular surgery and in plastic and reconstructive
surgery for their ability to reduce platelet aggregation and
promote blood flow in the microcirculation.1-7 Dextran 70
was first approved in the United States (US) in 1952 for
plasma volume expansion in the treatment of shock, fol-
lowed by Dextran 40 in 1967 for plasma volume expansion
and as prophylaxis against venous thrombosis and pulmo-
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1004nary embolism in patients undergoing surgeries with a high
risk for these complications.1,8-15
Anaphylactoid reactions have been recognized as infre-
quent but life-threatening responses to intravenous clinical
dextran therapy since the 1960s.7,16-19 Severe dextran-
induced anaphylactoid reactions (DIARs) are characterized
by bronchospasm, severe hypotension, cardiorespiratory
arrest, and/or death.17,20-22 Severe DIAR is an immune-
complex–mediated (type III) anaphylactoid reaction that
occurs when infused dextran molecules bind to endoge-
nous dextran-reactive immunoglobulin (Ig) G antibod-
ies.7,20,23
A large, retrospective Swedish cohort study conducted
between 1975 and 1979, when adverse event reporting was
mandatory in Sweden, found a higher risk of anaphylactoid
reactions after clinical dextrans than is typically seen after
medications. The rate of severe DIAR per unit of dextran
distributed was 13/100,000 doses sold for Dextran 40 and
25/100,000 doses sold for Dextran 70.21 Dextran is sup-
plied in 500 mL units. Since most patients received 1.5 to 2
units of Dextran 70, the rate of severe DIAR for Dextran 70
was estimated to be 37 to 50/100,000 treated patients
(95% confidence interval [CI] 31 to 58/100,000).21 This
rate is nearly twice the 19.6/100,000-background rate of
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international study from 199824 but may underestimate
the true incidence, since not all cases may have been re-
ported.21
Severe DIAR is nearly always prevented by preinfusing
dextran 1 (Promit, Meda AB Pharmaceuticals, Solna, Swe-
den), a low-molecular-weight (M.W. 1000) dextran moi-
ety.23 Dextran 1 acts to prevent severe DIAR by competi-
tively inhibiting clinical dextran from binding to IgG
antibodies.7,20
Despite elucidation of the mechanism for DIAR and
development of an effective prophylactic therapy, many
patients may receive clinical dextrans without dextran 1
pretreatment. The US professional package inserts for cur-
rently approved clinical dextran products do not recom-
mend preinfusion of dextran 1,8-14 and we found no study
describing the extent of dextran 1 use in patients receiving
clinical dextrans.
Recently published studies describe clinical dextran
administration without preinfusion of dextran 1. One clin-
ical trial found a higher rate of systemic reactions with
Dextran 40 than aspirin in 100 head and neck surgery
patients undergoing skin flap reconstruction16; dextran 1
was not administered to patients in this study. A prospective
Australian study of DIAR in obstetric and gynecologic
patients receiving Dextran 70 also did not use dextran 1.22
The American Society of Health System Pharmacists re-
cently reported that marketing of dextran 1 in the United
States has been discontinued,25 suggesting that dextran 1
may now be difficult or impossible to obtain, while admin-
istration of clinical dextrans continues.
Case reports submitted to the US Food and Drug
Administration (FDA) suggest that anaphylactoid events
associated with clinical dextrans have continued to occur
over the past three decades. We reviewed the FDA’s Ad-
verse Event Reporting System (AERS) to describe the
frequency and characteristics of these events.
METHODS
The AERS database contains reports of adverse events
received through “MedWatch,” the FDA’s safety informa-
tion and reporting system for drugs and biologic prod-
ucts.26 We screened AERS for reports received from 1969
(when AERSwas initiated) through 2004, with any dextran
listed as a suspect product and having at least one Medical
Dictionary for Regulatory Activities (MedDRA) Preferred
Term code related to anaphylaxis or anaphylactoid adverse
Table I. Screening terms for anaphylaxis/anaphylactoid
events
Anaphylactic reaction Laryngospasm Stridor
Anaphylactoid
reaction
Laryngeal edema Epiglottic edema
Anaphylactic shock Laryngotracheal edema Vasodilatation
Type I hypersensitivity Laryngeal obstruction Shockevents (Table I).We reviewed these reports for consistency with two case
definitions. Probable anaphylaxis/anaphylactoid events re-
quired involvement of signs or symptoms from at least two
body systems, with at least one sign or symptom being
hypotension, vasodilation, or respiratory difficulty; and on-
set within 60 minutes after starting a clinical dextran infu-
sion (Table II). Possible anaphylaxis/anaphylactoid events
were other events specifically described by the reporter as
anaphylaxis or anaphylactoid reactions.
The main outcome measure was frequency of probable
and possible anaphylaxis/anaphylactoid events. The key
characteristics evaluated included pretreatment with dex-
tran 1, the interval from clinical dextran administration
until onset of symptoms, and death.
Premier RxMarket Advisor (2000-2004, Premier
Healthcare Informatics, Premier Inc, Charlotte, NC) esti-
mated dextran usage in the United States from January 1,
2000 (the earliest date for which Premier RxMarket Advi-
sor data were available) to December 31, 2004. Premier
RxMarket Advisor estimates are based on discharge billing
data from a sample of 450 acute-care facilities and approx-
imately 16 million in-patient records. On an annual basis,
this constitutes roughly one of every seven in-patient dis-
charges in the United States. Hospitals in the Premier
sample are stratified by geographic region, urban vs rural,
teaching status, and bed size. Weights are then calculated
and applied to each hospital in the Premier RxMarket
Advisor sample, so that national projections closely repre-
sent the distribution of these characteristics among all US
hospitals from the American Hospital Association (AHA)
Annual Survey.
The IMS National Sales Perspective for 1999 to 2004
(Health, Fairfield, Conn)27 provided estimates of dextran
doses sold in the United States from January 1, 1999 (the
earliest date for which National Sales Perspective data were
available) to December 31, 2004. The National Sales Per-
spective measured the volume of drug products moving
from manufacturers into a large sample of drugstores, food
stores, mail services, clinics, hospitals, health maintenance
organizations, long-term care facilities, and other retail and
nonretail outlets.27 Purchase data from these outlets are
extrapolated to national sales estimates.
RESULTS
Between 1969 and 2004, the FDA received 366 ad-
verse event reports for clinical dextrans, of which 90
(24.6%) met the case definition for probable or possible
anaphylaxis/anaphylactoid event. Of these 90 reports, 66
(73.3%) were from the United States. Anaphylaxis or ana-
phylactoid events were reported in more males than fe-
males, particularly among US cases (Table III). Ages
ranged from 19 to 93 years, with a median of 66 years
worldwide and 63 years among US cases. A single publica-
tion on adverse drug events in the Netherlands accounted
for 20 of the 24 non-US cases.28 Patient age, gender, time
to onset, and year of event were not available for these
patients.
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in 55 cases, of which 45 (81.8%) received Dextran 40, 8
(14.5%) received Dextran 70, and 2 (3.6%) received Dex-
tran 75. Dextran was administered for thrombotic prophy-
laxis in 54 reports (94.7%) and for volume resuscitation in
four others (7.4%) (Table IV).
Probable anaphylaxis/anaphylactoid events accounted
for 39 reports (43.3%) and possible anaphylaxis/anaphylac-
toid events for 51 reports (56.7%). Of the US cases, 29
(43.9%) were probable and 37 (56.1%) were possible. The
time between the start of dextran infusion and the onset of
symptoms was available for 43 (47.8%) of the cases overall
and 39 (59.1%) of the US cases (Table V). All patients
developed symptoms within 60 minutes after infusion, and
26 (60.5%) began within 5 minutes.
Fifteen reports indicated that the patient died, of which
10 were from theUnited States. Two patients survived with
long-term sequelae, seven required prolonged hospitaliza-
tions, and 38 recovered (Table VI). Although therapy
administered was recorded for only 32 of the 75 nonfatal
cases, 25 (78.1%) had resuscitative measures, including
epinephrine, intravenous fluids, intubation, and/or cardio-
Table II. Signs and symptoms by body system
Cardiovascular Respiratory Dermato
Hypotension Tachypnea Urticaria
Vasodilatation Wheezing Lip edem
Flushing Stridor Facial ede
Tachycardia Laryngeal edema
Bradycardia Respiratory distress
Dyspnea
Table III. Characteristics of probable and possible
anaphylactic/anaphylactoid events after dextran
administration in reports to the FDA, 1969 to 2004
United States Other Total
N (%) N (%) N (%)
Gender
Male 37 (66.1) 1 (25.0) 38 (63.3)
Female 19 (33.9) 3 (75.0) 22 (36.7)
Unknown* 10 20 30
Year of event
1965-1974 16 (24.6) 1 (25.0) 17 (24.6)
1975-1984 18 (27.7) 0 18 (26.1)
1985-1994 25 (38.5) 2 (50.0) 27 (39.1)
1995-2004 6 (9.2) 1 (25.0) 7 (10.1)
Unknown* 1 20 21
Patient age (years)
25 2 (4.2) 0 2 (3.8)
25-49 8 (16.7) 2 (50.0) 10 (19.2)
50-74 30 (62.5) 2 (50.0) 32 (61.5)
74 8 (16.7) 0 8 (15.4)
Unknown* 18 20 38
Total 66 24 90
*Percentages exclude reports with unknown or missing data.pulmonary resuscitation.Four patients received dextran 1 premedication, 31 did
not, and 55 reports omitted this information. Of the 31
patients who did not receive dextran 1, 29 had adverse
events that occurred prior to 1984 (when dextran 1 was
first licensed in the United States),15 one received a test
dose of Dextran 40, and one, a fatality, did not receive any
pretreatment.
Billing data in the Premier Healthcare Informatics hos-
pital sample indicate an estimated 352,527 patients hospi-
talized in theUnited States were treated withDextran 40 or
70 from January 1, 2000 through 2004 (Table VII). Dex-
Gastrointestinal Other
Nausea Anxiety
Vomiting Feeling of impending doom
Abdominal pain Diaphoresis
Table IV. Indications for clinical dextran therapy
United
States Other Total
N N N
Indication
Thrombotic Prophylaxis
Adjunct to surgery 22 2 24
Thrombotic prophylaxis unspecified 7 0 7
Adjunct to cardiac catheterization/
angiography/angioplasty
11 0 11
Thrombophlebitis 7 0 7
Cardiovascular
insufficiency/transient ischemic
attack
2 0 2
Impaired Circulation 0 1 1
Antiplatelet aggregation 1 0 1
Volume resuscitation
Hypovolemic shock/plasma volume
expansion
4 0 4
Unknown 12 21 33
Total 66 24 90
Table V. Time to onset of symptoms
United States Other Total
N (%) N (%) N (%)
Time (minutes)
5* 24 (61.5) 2 (50.0) 26 (60.5)
5 to 10 6 (15.4) 1 (25.0) 7 (16.3)
10 to 30 0 1 (25.0) 1 (2.3)
30 to 60 9 (23.1) 0 9 (20.9)
Unknown† 27 20 47
Total 66 24 90
*Includes 4 cases described as “sudden” or “immediate.”
†Percentages exclude reports with unknown or missing data.logic
a
matran 1 was used in an estimated 12,433 hospitalizations
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Dextran 40 or 70 was administered to hospitalizations
where dextran 1 was administered was 28.4:1. The ex-
pected ratio would be 1:1 if all Dextran 40 or 70 patients
had received dextran 1 pretreatment. Any discharge where
dextran was billed at any time during the hospitalization
was counted as one use. If a patient received the product
more than once during the same hospitalization, it was still
counted only once. Hospitalizations with both dextran 1
and a clinical dextran administered were counted in both
categories.
Further, the estimates of national sales data from the
IMS National Sales Perspective (IMS Health)27 provided a
ratio of clinical dextran doses sold to dextran 1 doses sold of
38.6:1. Clinical dextran is supplied in 500 mL bags; each
bag is equivalent to one dose or one unit. A single patient
usually receives multiple units of clinical dextran for throm-
botic prophylaxis but would receive dextran 1 only once
(before the first clinical dextran administration). Therefore,
the ratio of clinical dextran doses sold to dextran 1 doses
sold would be expected to be 1:1. The maximum regi-
men of clinical dextrans recommended in package inserts is
about 10 units.11,13,14 As a result, with consistent use of
dextran 1, the ratio of clinical dextran doses sold to dextran
1 doses sold could be as high as 10:1. Larger ratios suggest
clinical dextran administrations without dextran 1 pretreat-
ments.
DISCUSSION
Reports to the FDA suggest that anaphylactoid events
after clinical dextrans continue to occur, despite the avail-
ability of dextran 1. Although previous studies have shown
that dextran 1 pretreatment reduces the risk of severe
adverse events associated with these products,29-32 its use
Table VI. Patient outcome
Outcome United States Other Total
(N) (N) (N)
Recovered, no sequelae noted 38 0 38
Prolonged hospitalization 6 1 7
Survived with sequelae 2 0 2
Died 10 5 15
Unknown 10 18 28
Total 66 24 90
Table VII. National estimates of dextran usage
Year
Number of hospitalizations
with a dextran product Ratio of Dextran 40 or 70
hospitalizations to dextran 1
hospitalizationsDextran 40 or 70 Dextran 1
2000 80,025 4575 17.5
2001 75,205 2591 29
2002 68,318 1278 53.4
2003 67,491 2592 26
2004 61,488 1398 44appears to be infrequent.Most patients in our series were50 years old, but age
does not necessarily increase the risk for anaphylactic events
after clinical dextran administration. Patients in this age
group would be likely to undergo surgical procedures
requiring antithrombotic prophylaxis and, thus, could be
more frequently exposed to clinical dextrans. The greater
frequency of anaphylactic/anaphylactoid events seen in
males vs females in our series corresponds to data from
previous studies. Ljungstrom et al reported a 3:1 male to
female ratio for severe DIAR in the Swedish retrospective
studies.21 This ratio may, again, reflect the types of patients
exposed to dextrans.
Anaphylactoid events were reported in all four decades
represented in this study. The number of reports was rela-
tively consistent through 1994 but declined during the
most recent 10-year period (1995 to 2004). The most
likely explanation for this decline may be reduced use of
clinical dextrans and a resultant decrease in the total num-
ber of adverse events occurring/reported. Decreased re-
porting might also be attributed to the product’s age, as
physicians using it may be familiar with known adverse
events and feel less compelled to report them.
The short time from the start of infusion to symptom
onset in many of the reports suggests that only a small dose
of clinical dextran is enough to incite a reaction. Most
reactions occurred within a few minutes of starting an
intravenous infusion of clinical dextran, so only a fraction of
the standard 500-mL dose would have been infused when
symptoms began.
Product utilization data from the past 5 years indicate
that dextran 1 has been used far less often than clinical
dextrans. Dextran 1 is indicated to lower the risk of ana-
phylactoid reactions to clinical dextrans and, as stated in the
product’s professional package insert, it reduces the risk of
DIAR from 1/2,000 to 1/70,000.23 Given this effective-
ness, why would dextran 1 use be low? One reason could be
that health-care providers simply lack awareness that dex-
tran 1 prophylaxis can prevent anaphylactoid reactions,
since dextran 1 is not mentioned in the US package inserts
for Dextran 40 or 70. Recent limitations in the availability
of dextran 1 may also be a contributing factor.
To help address these concerns, the FDA recently
presented this topic to its Blood Products Advisory Com-
mittee Meeting on July 21, 2005.15 The committee rec-
ommended that the FDA take steps to educate health-care
providers on the role of dextran 1 in preventing DIAR,
including asking clinical dextran manufacturers to add in-
formation about dextran 1 to their Dextran 40 and 70
package inserts.
Rationale for dextran 1 prophylaxis. Three large
clinical trials, cited in the product’s professional package
insert, have established dextran 1 as effective in reducing
the risk of DIAR.23,30-32 In one of these trials, 20 mL of
dextran 1 was administered before the infusion of Dextran
40 or Dextran 70 (n  41,076), and only one patient
developed DIAR (2/100,000; 95% CI, 0 to
13/100,000).32 This incidence is at least an order of mag-
nitude lower than the rate of DIAR found in the Swedish
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covigilance study conducted in Sweden after dextran 1
became available revealed a sharp decrease in the incidence
of DIAR. Hedin and Ljungstrom29 evaluated all spontane-
ous reports received between 1983 and 1992 by dextran
manufacturers and the World Health Organization’s ad-
verse event database, the International Drug Information
System (INTDIS). During this period, the incidence of
DIAR occurring after preinjection of dextran 1 in Sweden
(where reporting of serious adverse events is mandatory)
was 1/70,000, representing a 35-fold reduction in the
incidence of anaphylaxis.23,29
Limitations of our study. Our ability to assess the
association between the use of clinical dextrans and severe
DIAR in reports to the FDA is restricted by limitations of
passive safety surveillance, which include incomplete case
ascertainment and uneven data quality. Events reported to
AERS are subject to the reporter’s interpretation of the
patient’s signs and symptoms and are not always medically
verified. Some reports did not include important clinical
information, such as specific signs and symptoms, the time
interval between dextran infusion and symptom onset, or
the use of concomitant medications. We cannot assess the
effectiveness of dextran 1 in preventing anaphylactoid
events using this case series alone, since many reports did
not indicate the presence or absence of dextran 1 pretreat-
ment. Additionally, we cannot definitively conclude that all
anaphylaxis/anaphylactoid events in spontaneous reports
are dextran-induced, because patients may have reacted to
concomitant medications, or observed events could reflect
underlying illness.
AERS receives adverse event reports from product
manufacturers, health care professionals, and others. Re-
porting to the FDA is required of manufacturers, but
primary reporting to manufacturers by health-care provid-
ers and consumers is voluntary.26 Although the extent of
under-reporting is unknown, the actual number of anaphy-
lactic/anaphylactoid events associated with clinical dex-
trans may be much higher than the 90 reported here.
Under-reporting is affected by numerous factors, including
a product’s time on the market, publicity, and perceptions
in the prescribing community regarding product safety and
efficacy. Therefore, this case series does not provide inci-
dence rates for anaphylactoid events after the use of clinical
dextrans.
Not all reports contain enough detail to be classified by
severity, where severe DIAR includes severe hypotension,
bronchospasm, cardio-respiratory arrest, and/or death.20,21
Nonetheless, we believe that most of our reports are consis-
tent with severe DIAR. Probable cases required at least one
clinical sign (hypotension, respiratory difficulty, or vasodila-
tion) similar to the definition of severe DIAR, and possible
cases weremost often described by reporters as “anaphylaxis,”
a term usually reserved for severe allergic reactions. The high
proportion of cases that were fatal and the significant resusci-
tative measures used to treat most of the reactions further
attest to their severity.Previous studies with acknowledged limitations have
shown slightly higher anaphylactoid event rates for Dextran
70 vs Dextran 40.17,21,22,30 Our data do not allow reliable
comparisons of adverse event rates between products.
More than 80% of reports in our series were associated with
Dextran 40, but this distribution could simply reflect more
patients treated with Dextran 40 than Dextran 70.
The product utilization data are national projections
extrapolated from large samples of hospitals and pharma-
ceutical outlets. However, the ratio of clinical dextran
discharges to dextran 1 discharges was quite large and well
above what would be expected if dextran 1 use was equal to
clinical dextran use. The ratio of clinical dextran sales to
dextran 1 sales was similarly well above what would be
expected. It is unlikely that the marked difference between
clinical dextran use and dextran 1 use, demonstrated in two
different data sources, can be solely attributed to inaccura-
cies of the utilization data.
Despite these limitations, our case series demonstrates
that anaphylaxis or anaphylactoid events associated with
clinical dextrans continue to occur and to be reported to
FDA. Indeed, probable and possible cases account for
nearly one quarter of all clinical dextran adverse event
reports. The short interval from the start of the clinical
dextran infusion to the onset of anaphylactic/anaphylac-
toid symptoms in many of our cases seems consistent with a
causal association.
CONCLUSION
Spontaneous reports received by the FDA, combined
with evidence from published studies and product utiliza-
tion data, suggest that US cases of anaphylaxis or anaphy-
lactoid reaction continue to occur. One reason appears to
be infrequent pretreatment with dextran 1. To reduce the
risk of life-threatening systemic reactions, physicians should
consider administration of dextran 1 before the initiation of
clinical dextran therapy.
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